Clinical Phenotypes of Severe Cutaneous Drug Hypersensitivity Reactions

Author(s): Hakan Guvenir, Tugba Arikoglu, Emine Vezir, Emine Dibek Misirlioglu*.

Journal Name: Current Pharmaceutical Design

Volume 25 , Issue 36 , 2019

Become EABM
Become Reviewer

Abstract:

Drug hypersensitivity reactions are clinically heterogenous ranging from mild to severe. Most drug hypersensitivity reactions are accompanied by cutaneous manifestations. Fever, mucous membrane involvement, large blisters, facial oedema, pustulosis and visceral involvement are clinical features that lead to suspicion of severe adverse drug reactions. Severe cutaneous adverse drug reactions (SCARs) include Stevens-Johnson syndrome, toxic epidermal necrolysis, drug rash eosinophilia and systemic symptoms, acute generalized exanthematous pustulosis. Serum sickness like reactions, drug induced vasculitis and generalized bullous fixed drug eruptions are less severe clinical entities. SCARs are uncommon but associated with significant morbidity and mortality. Physician should be aware of specific red flags and danger signs to immediately identify these reactions. Immediate drug withdrawal is mandatory. Early diagnosis and appropriate treatment significantly affect the prognosis of the disease. The purpose of our review is to discuss clinical phenotypes of severe cutaneous drug hypersensitivity reactions.

Keywords: Acute generalized exanthematous pustulosis, drug rash eosinophilia and systemic symptoms, generalized bullous fixed drug eruption, stevens-Johnson syndrome, serum-sickness-like reaction, toxic epidermal necrolysis, vasculitis.

[1]
Stevens AM, Johnson FC. A new eruptive fever associated with stomatitis and ophthalmia. Am J Dis Child 1922; 24: 526-33.
[http://dx.doi.org/10.1001/archpedi.1922.04120120077005]
[2]
Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 1956; 68(11): 355-61.
[http://dx.doi.org/10.1111/j.1365-2133.1956.tb12766.x] [PMID: 13374196]
[3]
Paulmann M, Mockenhaupt M. Severe drug hypersensitivity reactions: clinical pattern, diagnosis, etiology and therapeutic options. Curr Pharm Des 2016; 22(45): 6852-61.
[http://dx.doi.org/10.2174/1381612822666160928125152] [PMID: 27779083]
[4]
Mockenhaupt M. The current understanding of stevens-johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol 2011; 7(6): 803-13.
[http://dx.doi.org/10.1586/eci.11.66] [PMID: 22014021]
[5]
Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, stevens-johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129(1): 92-6.
[http://dx.doi.org/10.1001/archderm.1993.01680220104023] [PMID: 8420497]
[6]
Rzany B, Mockenhaupt M, Baur S, et al. Epidemiology of erythema exsudativum multiforme majus, stevens-johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol 1996; 49(7): 769-73.
[http://dx.doi.org/10.1016/0895-4356(96)00035-2] [PMID: 8691227]
[7]
Strom BL, Carson JL, Halpern AC, et al. Using a claims database to investigate drug-induced stevens-johnson syndrome. Stat Med 1991; 10(4): 565-76.
[http://dx.doi.org/10.1002/sim.4780100408] [PMID: 2057655]
[8]
Chan HL, Stern RS, Arndt KA, et al. The incidence of erythema multiforme, stevens-johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990; 126(1): 43-7.
[http://dx.doi.org/10.1001/archderm.1990.01670250049006] [PMID: 2404462]
[9]
Schöpf E, Stühmer A, Rzany B, Victor N, Zentgraf R, Kapp JF. Toxic epidermal necrolysis and stevens-johnson syndrome. An epidemiologic study from west germany. Arch Dermatol 1991; 127(6): 839-42.
[http://dx.doi.org/10.1001/archderm.1991.01680050083008] [PMID: 2036029]
[10]
Frey N, Jossi J, Bodmer M, et al. The epidemiology of stevens-johnson syndrome and toxic epidermal necrolysis in the UK. J Invest Dermatol 2017; 137(6): 1240-7.
[http://dx.doi.org/10.1016/j.jid.2017.01.031] [PMID: 28202399]
[11]
Mittmann N, Knowles SR, Koo M, Shear NH, Rachlis A, Rourke SB. Incidence of toxic epidermal necrolysis and stevens-johnson syndrome in an HIV cohort: an observational, retrospective case series study. Am J Clin Dermatol 2012; 13(1): 49-54.
[http://dx.doi.org/10.2165/11593240-000000000-00000] [PMID: 22145749]
[12]
Duong TA, Valeyrie-Allanore L, Wolkenstein P, Chosidow O. Severe cutaneous adverse reactions to drugs. Lancet 2017; 390(10106): 1996-2011.
[http://dx.doi.org/10.1016/S0140-6736(16)30378-6] [PMID: 28476287]
[13]
Gillis NK, Hicks JK, Bell GC, Daly AJ, Kanetsky PA, McLeod HL. Incidence and triggers of stevens-johnson syndrome and toxic epidermal necrolysis in a large cancer patient cohort. J Invest Dermatol 2017; 137(9): 2021-3.
[http://dx.doi.org/10.1016/j.jid.2017.05.010] [PMID: 28549953]
[14]
Sekula P, Dunant A, Mockenhaupt M, et al. Comprehensive survival analysis of a cohort of patients with stevens-johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol 2013; 133(5): 1197-204.
[http://dx.doi.org/10.1038/jid.2012.510] [PMID: 23389396]
[15]
Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol 2013; 69(2): 173.
[http://dx.doi.org/10.1016/j.jaad.2013.05.003] [PMID: 23866878]
[16]
Bouvy JC, De Bruin ML, Koopmanschap MA. Epidemiology of adverse drug reactions in Europe: a review of recent observational studies. Drug Saf 2015; 38(5): 437-53.
[http://dx.doi.org/10.1007/s40264-015-0281-0] [PMID: 25822400]
[17]
Hernández-Salazar A, Rosales SP-L, Rangel-Frausto S, Criollo E, Archer-Dubon C, Orozco-Topete R. Epidemiology of adverse cutaneous drug reactions. A prospective study in hospitalized patients. Arch Med Res 2006; 37(7): 899-902.
[http://dx.doi.org/10.1016/j.arcmed.2006.03.010] [PMID: 16971233]
[18]
Mockenhaupt M, Dunant A, Paulmann M, et al. Drug causality in stevens-johnson syndrome/toxic epidermal necrolysis in europe: analysis of 10 years regiscar-study. Pharmacoepidemiol Drug Saf 2016; 25(Suppl. 3): 3.
[19]
Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008; 128(1): 35-44.
[http://dx.doi.org/10.1038/sj.jid.5701033] [PMID: 17805350]
[20]
Dibek Misirlioglu E, Guvenir H, Bahceci S, et al. Severe cutaneous adverse drug reactions in pediatric patients: a multicenter study. J Allergy Clin Immunol Pract 2017; 5(3): 757-63.
[http://dx.doi.org/10.1016/j.jaip.2017.02.013] [PMID: 28351788]
[21]
Data from the RegiSCAR Project. Available at: http://www.regiscar.org/index.html
[22]
Mockenhaupt M. Stevens-johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management. Semin Cutan Med Surg 2014; 33(1): 10-6.
[http://dx.doi.org/10.12788/j.sder.0058] [PMID: 25037254]
[23]
Woolum JA, Bailey AM, Baum RA, Metts ELA. A review of the management of stevens-johnson syndrome and toxic epidermal necrolysis. Adv Emerg Nurs J 2019; 41(1): 56-64.
[http://dx.doi.org/10.1097/TME.0000000000000225] [PMID: 30702535]
[24]
Alerhand S, Cassella C, Koyfman A. Stevens-johnson syndrome and toxic epidermal necrolysis in the pediatric population: a review. Pediatr Emerg Care 2016; 32(7): 472-6.
[http://dx.doi.org/10.1097/PEC.0000000000000840] [PMID: 27380605]
[25]
Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, Shear NH. Stevens-johnson syndrome and toxic epidermal necrolysis: an update. Am J Clin Dermatol 2015; 16(6): 475-93.
[http://dx.doi.org/10.1007/s40257-015-0158-0] [PMID: 26481651]
[26]
Morales ME, Purdue GF, Verity SM, Arnoldo BD, Blomquist PH. Ophthalmic manifestations of stevens-johnson syndrome and toxic epidermal necrolysis and relation to SCORTEN. Am J Ophthalmol 2010; 150(4): 505-10.
[http://dx.doi.org/10.1016/j.ajo.2010.04.026] [PMID: 20619392]
[27]
Sotozono C, Ueta M, Nakatani E, et al. Predictive factors associated with acute ocular involvement in stevens-johnson syndrome and toxic epidermal necrolysis. Am J Ophthalmol 2015; 160(2): 228-37.
[http://dx.doi.org/10.1016/j.ajo.2015.05.002] [PMID: 25979679]
[28]
de Prost N, Mekontso-Dessap A, Valeyrie-Allanore L, et al. Acute respiratory failure in patients with toxic epidermal necrolysis: clinical features and factors associated with mechanical ventilation. Crit Care Med 2014; 42(1): 118-28.
[http://dx.doi.org/10.1097/CCM.0b013e31829eb94f] [PMID: 23989174]
[29]
Jha AK, Goenka MK. Colonic involvement in stevens-johnson syndrome: a rare entity. Dig Endosc 2012; 24(5): 382.
[http://dx.doi.org/10.1111/j.1443-1661.2012.01248.x] [PMID: 22925298]
[30]
Côté B, Wechsler J, Bastuji-Garin S, Assier H, Revuz J, Roujeau JC. Clinicopathologic correlation in erythema multiforme and stevens-johnson syndrome. Arch Dermatol 1995; 131(11): 1268-72.
[http://dx.doi.org/10.1001/archderm.1995.01690230046008] [PMID: 7503570]
[31]
Creamer D, Walsh SA, Dziewulski P, et al. UK guidelines for the management of stevens-johnson syndrome/toxic epidermal necrolysis in adults 2016. Br J Dermatol 2016; 174(6): 1194-227.
[http://dx.doi.org/10.1111/bjd.14530] [PMID: 27317286]
[32]
Gupta LK, Martin AM, Agarwal N, et al. Guidelines for the management of stevens-johnson syndrome/toxic epidermal necrolysis: an indian perspective. Indian J Dermatol Venereol Leprol 2016; 82(6): 603-25.
[http://dx.doi.org/10.4103/0378-6323.191134] [PMID: 27716721]
[33]
Struck MF, Illert T, Schmidt T, Reichelt B, Steen M. Secondary abdominal compartment syndrome in patients with toxic epidermal necrolysis. Burns 2012; 38(4): 562-7.
[http://dx.doi.org/10.1016/j.burns.2011.10.004] [PMID: 22075117]
[34]
de Prost N, Ingen-Housz-Oro S. Duong Ta, et al. Bacteremia in stevens-johnson syndrome and toxic epidermal necrolysis: epidemiology, risk factors, and predictive value of skin cultures. Medicine (Baltimore) 2010; 89(1): 28-36.
[http://dx.doi.org/10.1097/MD.0b013e3181ca4290] [PMID: 20075702]
[35]
Bouziri A, Khaldi A, Hamdi A, et al. Toxic epidermal necrolysis complicated by small bowel intussusception: a case report. J Pediatr Surg 2011; 46(2): e9-e11.
[http://dx.doi.org/10.1016/j.jpedsurg.2010.09.011] [PMID: 21292071]
[36]
Chosidow O, Delchier JC, Chaumette MT, et al. Intestinal involvement in drug-induced toxic epidermal necrolysis. Lancet 1991; 337(8746): 928.
[http://dx.doi.org/10.1016/0140-6736(91)90273-R] [PMID: 1673016]
[37]
Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol 2013; 69(2): 187.
[http://dx.doi.org/10.1016/j.jaad.2013.05.002] [PMID: 23866879]
[38]
Lee HY, Walsh SA, Creamer D. Long-term complications of stevens-johnson syndrome/toxic epidermal necrolysis (SJS/TEN): the spectrum of chronic problems in patients who survive an episode of SJS/TEN necessitates multidisciplinary follow-up. Br J Dermatol 2017; 177(4): 924-35.
[http://dx.doi.org/10.1111/bjd.15360] [PMID: 28144971]
[39]
Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in stevens-johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 2010; 88(1): 60-8.
[http://dx.doi.org/10.1038/clpt.2009.252] [PMID: 20375998]
[40]
Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis (AGEP): a review and update. J Am Acad Dermatol 2015; 73(5): 843-8.
[http://dx.doi.org/10.1016/j.jaad.2015.07.017] [PMID: 26354880]
[41]
Garg T, Sanke S, Ahmed R, Chander R, Basu S. stevens-johnson syndrome and toxic epidermal necrolysis-like cutaneous presentation of chikungunya fever: A case series. Pediatr Dermatol 2018; 35(3): 392-6.
[http://dx.doi.org/10.1111/pde.13450] [PMID: 29573443]
[42]
Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and mortality of stevens-johnson syndrome and toxic epidermal necrolysis in united states adults. J Invest Dermatol 2016; 136(7): 1387-97.
[http://dx.doi.org/10.1016/j.jid.2016.03.023] [PMID: 27039263]
[43]
Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115(2): 149-53.
[http://dx.doi.org/10.1046/j.1523-1747.2000.00061.x] [PMID: 10951229]
[44]
Guégan S, Bastuji-Garin S, Poszepczynska-Guigné E, Roujeau JC, Revuz J. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol 2006; 126(2): 272-6.
[http://dx.doi.org/10.1038/sj.jid.5700068] [PMID: 16374461]
[45]
Bansal S, Garg VK, Sardana K, Sarkar R. A clinicotherapeutic analysis of stevens-johnson syndrome and toxic epidermal necrolysis with an emphasis on the predictive value and accuracy of SCORe of toxic epidermal necrolysis. Int J Dermatol 2015; 54(1): e18-26.
[http://dx.doi.org/10.1111/ijd.12466] [PMID: 25534407]
[46]
Peter JG, Lehloenya R, Dlamini S, et al. Severe delayed cutaneous and systemic reactions to drugs: a global perspective on the science and art of current practice. J Allergy Clin Immunol Pract 2017; 5(3): 547-63.
[http://dx.doi.org/10.1016/j.jaip.2017.01.025] [PMID: 28483310]
[47]
Kano Y, Ishida T, Hirahara K, Shiohara T. Visceral involvements and long-term sequelae in drug-induced hypersensitivity syndrome. Med Clin North Am 2010; 94(4): 743-59.
[http://dx.doi.org/10.1016/j.mcna.2010.03.004] [PMID: 20609861]
[48]
Paulmann M, Mockenhaupt M. Severe drug-induced skin reactions: clinical features, diagnosis, etiology, and therapy. J Dtsch Dermatol Ges 2015; 13(7): 625-45.
[http://dx.doi.org/10.1111/ddg.12747] [PMID: 26110722]
[49]
Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 2013; 169(5): 1071-80.
[http://dx.doi.org/10.1111/bjd.12501] [PMID: 23855313]
[50]
Kano Y, Hiraharas K, Sakuma K, Shiohara T. Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease. Br J Dermatol 2006; 155(2): 301-6.
[http://dx.doi.org/10.1111/j.1365-2133.2006.07238.x] [PMID: 16882166]
[51]
Adler NR, Aung AK, Ergen EN, Trubiano J, Goh MSY, Phillips EJ. Recent advances in the understanding of severe cutaneous adverse reactions. Br J Dermatol 2017; 177(5): 1234-47.
[http://dx.doi.org/10.1111/bjd.15423] [PMID: 28256714]
[52]
Tohyama M, Hashimoto K, Yasukawa M, et al. Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome. Br J Dermatol 2007; 157(5): 934-40.
[http://dx.doi.org/10.1111/j.1365-2133.2007.08167.x] [PMID: 17854362]
[53]
Gaig P, García-Ortega P, Baltasar M, Bartra J. Drug neosensitization during anticonvulsant hypersensitivity syndrome. J Investig Allergol Clin Immunol 2006; 16(5): 321-6.
[PMID: 17039674]
[54]
Cho YT, Yang CW, Chu CY. Drug reaction with eosinophilia and systemic symptoms (DRESS): an interplay among drugs, viruses, and immune system. Int J Mol Sci 2017; 18(6)e1243
[http://dx.doi.org/10.3390/ijms18061243] [PMID: 28598363]
[55]
Brockow K, Ardern-Jones MR, Mockenhaupt M, et al. EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity. Allergy 2019; 74(1): 14-27.
[http://dx.doi.org/10.1111/all.13562] [PMID: 30028512]
[56]
Sasidharanpillai S, Sabitha S, Riyaz N, et al. Drug reaction with eosinophilia and systemic symptoms in children: a prospective study. Pediatr Dermatol 2016; 33(2): e162-5.
[http://dx.doi.org/10.1111/pde.12803] [PMID: 27001334]
[57]
Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: part I. Clinical perspectives. J Am Acad Dermatol 2013; 68(5): 693, e1- 693.
[http://dx.doi.org/10.1016/j.jaad.2013.01.033] [PMID: 23602182]
[58]
Bachot N, Roujeau JC. Differential diagnosis of severe cutaneous drug eruptions. Am J Clin Dermatol 2003; 4(8): 561-72.
[http://dx.doi.org/10.2165/00128071-200304080-00006] [PMID: 12862499]
[59]
Kardaun SH, Sidoroff A, Valeyrie-Allanore L, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2007; 156(3): 609-11.
[http://dx.doi.org/10.1111/j.1365-2133.2006.07704.x] [PMID: 17300272]
[60]
Mockenhaupt M. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. J Dtsch Dermatol Ges 2009; 7(2): 142-60.
[http://dx.doi.org/10.1111/j.1610-0387.2008.06878.x] [PMID: 19371237]
[61]
Descloux E, Argaud L, Dumortier J, Scoazec JY, Boillot O, Robert D. Favourable issue of a fulminant hepatitis associated with sulfasalazine DRESS syndrome without liver transplantation. Intensive Care Med 2005; 31(12): 1727-8.
[http://dx.doi.org/10.1007/s00134-005-2846-3] [PMID: 16283166]
[62]
Cacoub P, Musette P, Descamps V, et al. The DRESS syndrome: a literature review. Am J Med 2011; 124(7): 588-97.
[http://dx.doi.org/10.1016/j.amjmed.2011.01.017] [PMID: 21592453]
[63]
Chen YC, Chiu HC, Chu CY. Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases. Arch Dermatol 2010; 146(12): 1373-9.
[http://dx.doi.org/10.1001/archdermatol.2010.198] [PMID: 20713773]
[64]
Sakuma K, Kano Y, Fukuhara M, Shiohara T. Syndrome of inappropriate secretion of antidiuretic hormone associated with limbic encephalitis in a patient with drug-induced hypersensitivity syndrome. Clin Exp Dermatol 2008; 33(3): 287-90.
[http://dx.doi.org/10.1111/j.1365-2230.2007.02645.x] [PMID: 18201256]
[65]
Shiohara T, Iijima M, Ikezawa Z, Hashimoto K. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Br J Dermatol 2007; 156(5): 1083-4.
[http://dx.doi.org/10.1111/j.1365-2133.2007.07807.x] [PMID: 17381452]
[66]
Shiohara T, Takahashi R, Kano Y. Drug-induced hypersensitivity syndrome and viral reactivationdrug hypersensitivity. Basel: Karger 2007; pp. 251-66.
[http://dx.doi.org/10.1159/000104205]
[67]
Sidoroff A, Dunant A, Viboud C, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol 2007; 157(5): 989-96.
[http://dx.doi.org/10.1111/j.1365-2133.2007.08156.x] [PMID: 17854366]
[68]
Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: part II. Management and therapeutics. J Am Acad Dermatol 2013; 68(5): 709, e1-9.
[http://dx.doi.org/10.1016/j.jaad.2013.01.032] [PMID: 23602183]
[69]
Kano Y, Shiohara T. The variable clinical picture of drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms in relation to the eliciting drug. Immunol Allergy Clin North Am 2009; 29(3): 481-501.
[http://dx.doi.org/10.1016/j.iac.2009.04.007] [PMID: 19563993]
[70]
Aota N, Shiohara T. Viral connection between drug rashes and autoimmune diseases: how autoimmune responses are generated after resolution of drug rashes. Autoimmun Rev 2009; 8(6): 488-94.
[http://dx.doi.org/10.1016/j.autrev.2009.02.029] [PMID: 19239928]
[71]
van der Werf N, Kroese FGM, Rozing J, Hillebrands JL. Viral infections as potential triggers of type 1 diabetes. Diabetes Metab Res Rev 2007; 23(3): 169-83.
[http://dx.doi.org/10.1002/dmrr.695] [PMID: 17103489]
[72]
Aota N, Hirahara K, Kano Y, Fukuoka T, Yamada A, Shiohara T. Systemic lupus erythematosus presenting with kikuchi-fujimoto’s disease as a long-term sequela of drug-induced hypersensitivity syndrome. A possible role of epstein-barr virus reactivation. Dermatology (Basel) 2009; 218(3): 275-7.
[http://dx.doi.org/10.1159/000187619] [PMID: 19088463]
[73]
Roujeau JC, Bioulac-Sage P, Bourseau C, et al. Acute generalized exanthematous pustulosis. Analysis of 63 cases. Arch Dermatol 1991; 127(9): 1333-8.
[http://dx.doi.org/10.1001/archderm.1991.01680080069004] [PMID: 1832534]
[74]
Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP)-a clinical reaction pattern. J Cutan Pathol 2001; 28(3): 113-9.
[http://dx.doi.org/10.1034/j.1600-0560.2001.028003113.x] [PMID: 11168761]
[75]
Macmillan AL. Generalised pustular drug rash. Dermatologica 1973; 146(5): 285-91.
[http://dx.doi.org/10.1159/000251978] [PMID: 4270576]
[76]
Bissonnette R, Tousignant J, Allaire G. Drug-induced toxic pustuloderma. Int J Dermatol 1992; 31(3): 172-4.
[http://dx.doi.org/10.1111/j.1365-4362.1992.tb03926.x] [PMID: 1568810]
[77]
Chang SL, Huang YH, Yang CH, Hu S, Hong HS. Clinical manifestations and characteristics of patients with acute generalized exanthematous pustulosis in asia. Acta Derm Venereol 2008; 88(4): 363-5.
[PMID: 18709306]
[78]
Alniemi DT, Wetter DA, Bridges AG, et al. Acute generalized exanthematous pustulosis: clinical characteristics, etiologic associations, treatments, and outcomes in a series of 28 patients at mayo clinic, 1996-2013. Int J Dermatol 2017; 56(4): 405-14.
[http://dx.doi.org/10.1111/ijd.13434] [PMID: 28084022]
[79]
Paradisi A, Bugatti L, Sisto T, Filosa G, Amerio PL, Capizzi R. Acute generalized exanthematous pustulosis induced by hydroxychloroquine: three cases and a review of the literature. Clin Ther 2008; 30(5): 930-40.
[http://dx.doi.org/10.1016/j.clinthera.2008.05.014] [PMID: 18555940]
[80]
Smeets TJ, Jessurun N, Härmark L, Kardaun SH. Clindamycin-induced acute generalised exanthematous pustulosis: five cases and a review of the literature. Neth J Med 2016; 74(10): 421-8.
[PMID: 27966434]
[81]
Bär M, John L, Wonschik S, et al. Acute generalized exanthematous pustulosis induced by high-dose prednisolone in a young woman with optic neuritis owing to disseminated encephalomyelitis. Br J Dermatol 2008; 159(1): 251-2.
[http://dx.doi.org/10.1111/j.1365-2133.2008.08594.x] [PMID: 18489605]
[82]
Buettiker U, Keller M, Pichler WJ, Braathen LR, Yawalkar N. Oral prednisolone induced acute generalized exanthematous pustulosis due to corticosteroids of group a confirmed by epicutaneous testing and lymphocyte transformation tests. Dermatology (Basel) 2006; 213(1): 40-3.
[http://dx.doi.org/10.1159/000092837] [PMID: 16778426]
[83]
Speck LM, Wilkerson MG, Perri AJ, Kelly BC. Acute generalized exanthematous pustulosis caused by terazosin hydrochloride. J Drugs Dermatol 2008; 7(4): 395-7.
[PMID: 18459523]
[84]
Nantes Castillejo O, Zozaya Urmeneta JM, Valcayo Peñalba A, Martínez-Peñuela Virseda JM. Acute generalized exanthematous pustulosis induced by omeprazole Gastroenterol Hepatol 2008; 31(5): 295-8.
[http://dx.doi.org/10.1157/13119883] [PMID: 18448060]
[85]
Sugita K, Nishio D, Kabashima K, Tokura Y. Acute generalized exanthematous pustulosis caused by sennoside in a patient with multiple myeloma. J Eur Acad Dermatol Venereol 2008; 22(4): 517-9.
[http://dx.doi.org/10.1111/j.1468-3083.2007.02378.x] [PMID: 18363928]
[86]
Schmitz B, Sorrells T, Glass JS. Acute generalized exanthematous pustulosis caused by pantoprazole. Cutis 2018; 101(5): e22-3.
[PMID: 29894542]
[87]
Chen CB, Wu MY, Ng CY, et al. Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies. Cancer Manag Res 2018; 10: 1259-73.
[http://dx.doi.org/10.2147/CMAR.S163391] [PMID: 29844705]
[88]
Sarradin V, Dalenc F, Sibaud V, Tournier E, Roché H. Acute generalized exanthematous pustulosis induced by docetaxel and recurrent with letrozole: a case report. Clin Breast Cancer 2018; 18(5): e743-6.
[http://dx.doi.org/10.1016/j.clbc.2018.06.009] [PMID: 29980428]
[89]
Choi MJ, Kim HS, Park HJ, et al. Clinicopathologic manifestations of 36 korean patients with acute generalized exanthematous pustulosis: a case series and review of the literature. Ann Dermatol 2010; 22(2): 163-9.
[http://dx.doi.org/10.5021/ad.2010.22.2.163] [PMID: 20548906]
[90]
Pennisi RS. Acute generalised exanthematous pustulosis induced by the herbal remedy Ginkgo biloba. Med J Aust 2006; 184(11): 583-4.
[http://dx.doi.org/10.5694/j.1326-5377.2006.tb00386.x] [PMID: 16768668]
[91]
Park MY, Kang HY. Acute generalized exanthematous pustulosisafter ingestion of lacquer chicken. Ann Dermatol 2008; 20(4): 209-11.
[http://dx.doi.org/10.5021/ad.2008.20.4.209] [PMID: 27303194]
[92]
O’Driscoll D, Foria V, Fityan A, Ardern-Jones M. Accidental re-exposure causing repeated severe acute generalized exanthematous pustulosis. Clin Exp Dermatol 2019; 44(8): 927-9.
[http://dx.doi.org/10.1111/ced.13920] [PMID: 30817022]
[93]
Machet P, Marcé D, Ziyani Y, et al. Acute generalized exanthematous pustulosis induced by iomeprol with cross-reactivity to other iodinated contrast agents and mild reactions after rechallenge with iopromide and oral corticosteroid premedication. Contact Dermat 2019; 81(1): 74-6.
[http://dx.doi.org/10.1111/cod.13242] [PMID: 30762885]
[94]
Bordel Gómez MT, Martín García C, Meseguer Yebra C, Zafra Cobo MI, Cardeñoso Álvarez ME, Sánchez Estella J. First case report of acute generalized exanthematous pustulosis (AGEP) caused by gadolinium confirmed by patch testing. Contact Dermat 2018; 78(2): 166-8.
[http://dx.doi.org/10.1111/cod.12878] [PMID: 29341190]
[95]
Nakai N, Sugiura K, Akiyama M, Katoh N. Acute generalized exanthematous pustulosis caused by dihydrocodeine phosphate in a patient with psoriasis vulgaris and a heterozygous IL36RN mutation. JAMA Dermatol 2015; 151(3): 311-5.
[http://dx.doi.org/10.1001/jamadermatol.2014.3002] [PMID: 25409173]
[96]
Pettit C, Massick S, Bechtel M. Cannabidiol-induced acute generalized exanthematous pustulosis. Dermatitis 2018; 29(6): 345-6.
[http://dx.doi.org/10.1097/DER.0000000000000422] [PMID: 30422887]
[97]
Shindo T, Masuda Y, Imai Y, Nagano T, Nishioka H. Case report: acute generalized exanthematous pustulosis caused by praziquantel. Am J Trop Med Hyg 2019; 100(3): 700-2.
[http://dx.doi.org/10.4269/ajtmh.18-0832] [PMID: 30675838]
[98]
Allouchery M, Hainaut Wierzbicka E, Frouin E, Perault Pochat MC. Acute generalized exanthematous pustulosis induced by mianserin. Eur J Dermatol 2018; 28(4): 556-7.
[http://dx.doi.org/10.1684/ejd.2018.3339] [PMID: 30129529]
[99]
Özkaya E, Yazganoğlu KD, Kutlay A, Mahmudov A. Varenicline-induced acute generalized exanthematous pustulosis confirmed by patch testing. Contact Dermat 2018; 78(1): 97-9.
[http://dx.doi.org/10.1111/cod.12867] [PMID: 29265452]
[100]
Lee SK, Kim MS, Lee UH. Acute generalized exanthematous pustulosis induced by a digestive enzyme drug, Festal®. Clin Exp Dermatol 2018; 43(3): 321-3.
[http://dx.doi.org/10.1111/ced.13372] [PMID: 29341242]
[101]
Suh HY, Bae J, Kim HL, et al. A case of acute generalized exanthematous pustulosis after injection of an erythropoiesis-stimulating agent. Ann Dermatol 2018; 30(1): 100-1.
[http://dx.doi.org/10.5021/ad.2018.30.1.100] [PMID: 29386844]
[102]
Di Lernia V, Ricci C. Fluconazole-induced acute generalized exanthematous pustulosis. Indian J Dermatol 2015; 60(2): 212.
[PMID: 25814733]
[103]
Schwarz M, Kreuzer KA, Baskaynak G, Dörken B, le Coutre P. Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia. Eur J Haematol 2002; 69(4): 254-6.
[http://dx.doi.org/10.1034/j.1600-0609.2002.02830.x] [PMID: 12431246]
[104]
Betto P, Germi L, Bonoldi E, Bertazzoni M. Acute localized exanthematous pustulosis (ALEP) caused by amoxicillin-clavulanic acid. Int J Dermatol 2008; 47(3): 295-6.
[http://dx.doi.org/10.1111/j.1365-4632.2008.03477.x] [PMID: 18289337]
[105]
Rastogi S, Modi M, Dhawan V. Acute localized exanthematous pustulosis (ALEP) caused by Ibuprofen. A case report. Br J Oral Maxillofac Surg 2009; 47(2): 132-4.
[http://dx.doi.org/10.1016/j.bjoms.2008.07.185] [PMID: 18783858]
[106]
Cohen AD, Cagnano E, Halevy S. Acute generalized exanthematous pustulosis mimicking toxic epidermal necrolysis. Int J Dermatol 2001; 40(7): 458-61.
[http://dx.doi.org/10.1046/j.1365-4362.2001.01241.x] [PMID: 11679003]
[107]
Lateef A, Tan KB, Lau TC. Acute generalized exanthematous pustulosis and toxic epidermal necrolysis induced by hydroxychloroquine. Clin Rheumatol 2009; 28(12): 1449-52.
[http://dx.doi.org/10.1007/s10067-009-1262-4] [PMID: 19727917]
[108]
Bouvresse S, Valeyrie-Allanore L, Ortonne N, et al. Toxic epidermal necrolysis, DRESS, AGEP: do overlap cases exist? Orphanet J Rare Dis 2012; 7: 72.
[http://dx.doi.org/10.1186/1750-1172-7-72] [PMID: 23009177]
[109]
Eeckhout I, Noens L, Ongenae K, al Sarraf Z, Schelfhout A, Naeyaert JM. Acute generalized exanthematic pustulosis: a case with a lymphoma-like presentation. Dermatology (Basel) 1997; 194(4): 408-10.
[http://dx.doi.org/10.1159/000246163] [PMID: 9252778]
[110]
Syrigou E, Grapsa D, Charpidou A, Syrigos K. Acute generalized exanthematous pustulosis induced by amoxicillin/clavulanic acid: report of a case presenting with generalized lymphadenopathy. J Cutan Med Surg 2015; 19(6): 592-4.
[http://dx.doi.org/10.1177/1203475415588003] [PMID: 25997755]
[111]
Hotz C, Valeyrie-Allanore L, Haddad C, et al. Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patients. Br J Dermatol 2013; 169(6): 1223-32.
[http://dx.doi.org/10.1111/bjd.12502] [PMID: 23855377]
[112]
Halevy S. Acute generalized exanthematous pustulosis. Curr Opin Allergy Clin Immunol 2009; 9(4): 322-8.
[http://dx.doi.org/10.1097/ACI.0b013e32832cf64e] [PMID: 19458527]
[113]
Kardaun SH, Kuiper H, Fidler V, Jonkman MF. The histopathological spectrum of acute generalized exanthematous pustulosis (AGEP) and its differentiation from generalized pustular psoriasis. J Cutan Pathol 2010; 37(12): 1220-9.
[http://dx.doi.org/10.1111/j.1600-0560.2010.01612.x] [PMID: 20738458]
[114]
Spencer JM, Silvers DN, Grossman ME. Pustular eruption after drug exposure: is it pustular psoriasis or a pustular drug eruption? Br J Dermatol 1994; 130(4): 514-9.
[http://dx.doi.org/10.1111/j.1365-2133.1994.tb03389.x] [PMID: 8186121]
[115]
Halevy S, Kardaun SH, Davidovici B, Wechsler J. The spectrum of histopathological features in acute generalized exanthematous pustulosis: a study of 102 cases. Br J Dermatol 2010; 163(6): 1245-52.
[http://dx.doi.org/10.1111/j.1365-2133.2010.09967.x] [PMID: 20698849]
[116]
Treudler R, Grunewald S, Gebhardt C, Simon JC. Prolonged course of acute generalized exanthematous pustulosis with liver involvement due to sensitization to amoxicillin and paracetamol. Acta Derm Venereol 2009; 89(3): 314-5.
[http://dx.doi.org/10.2340/00015555-0616] [PMID: 19479138]
[117]
Mohaghegh F, Jelvan M, Rajabi P. A case of prolonged generalized exanthematous pustulosis caused by hydroxychloroquine-literature review. Clin Case Rep 2018; 6(12): 2391-5.
[http://dx.doi.org/10.1002/ccr3.1811] [PMID: 30564334]
[118]
Speeckaert MM, Speeckaert R, Lambert J, Brochez L. Acute generalized exanthematous pustulosis: an overview of the clinical, immunological and diagnostic concepts. Eur J Dermatol 2010; 20(4): 425-33.
[http://dx.doi.org/10.1684/ejd.2010.0932] [PMID: 20542841]
[119]
Brandenburg VM, Kurts C, Eitner F, Hamilton-Williams E, Heintz B. Acute reversible renal failure in acute generalized exanthematous pustulosis. Nephrol Dial Transplant 2002; 17(10): 1857-8.
[http://dx.doi.org/10.1093/ndt/17.10.1857] [PMID: 12271006]
[120]
Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology 2005; 209(2): 123-9.
[http://dx.doi.org/10.1016/j.tox.2004.12.022] [PMID: 15767024]
[121]
Park JJ, Yun SJ, Lee JB, Kim SJ, Won YH, Lee SC. A case of hydroxychloroquine induced acute generalized exanthematous pustulosis confirmed by accidental oral provocation. Ann Dermatol 2010; 22(1): 102-5.
[http://dx.doi.org/10.5021/ad.2010.22.1.102] [PMID: 20548896]
[122]
Von Pirquet CF, Schick B. (Die Serumkrankheit). Serum Sickness, Schick B (Ed), Williams & Wilkins, Leipzig 1905 (translation Baltimore) 1951.
[123]
Frieling GW. Pediatric drug eruptions of the skincutaneous drug eruptions: diagnosis, histopathology and therapy. Springer 2015; pp. 431-44.
[http://dx.doi.org/10.1007/978-1-4471-6729-7_38]
[124]
Knowles SR, Shear NH. Major adverse cutaneous effects from systemic drugs.Wolverton SE. 3rd ed. Comprehensive dermatologic drug therapy: Elsevier 2013; 749-750.
[125]
King BA, Geelhoed GC. Adverse skin and joint reactions associated with oral antibiotics in children: the role of cefaclor in serum sickness-like reactions. J Paediatr Child Health 2003; 39(9): 677-81.
[http://dx.doi.org/10.1046/j.1440-1754.2003.00267.x] [PMID: 14629499]
[126]
Brucculeri M, Charlton M, Serur D. Serum sickness-like reaction associated with cefazolin. BMC Clin Pharmacol 2006; 6: 3.
[http://dx.doi.org/10.1186/1472-6904-6-3] [PMID: 16504095]
[127]
Kearns GL, Wheeler JG, Childress SH, Letzig LG. Serum sickness-like reactions to cefaclor: role of hepatic metabolism and individual susceptibility. J Pediatr 1994; 125(5 Pt 1): 805-11.
[http://dx.doi.org/10.1016/S0022-3476(06)80187-3] [PMID: 7965438]
[128]
Yorulmaz A, Akın F, Sert A, Ağır MA, Yılmaz R, Arslan Ş. Demographic and clinical characteristics of patients with serum sickness-like reaction. Clin Rheumatol 2018; 37(5): 1389-94.
[http://dx.doi.org/10.1007/s10067-017-3777-4] [PMID: 28795234]
[129]
Tolpinrud WL, Bunick CG, King BA. Serum sickness-like reaction: histopathology and case report. J Am Acad Dermatol 2011; 65(3): e83-5.
[http://dx.doi.org/10.1016/j.jaad.2011.02.037] [PMID: 21839305]
[130]
Nguyen CV, Miller DD. Serum sickness-like drug reaction: two cases with a neutrophilic urticarial pattern. J Cutan Pathol 2017; 44(2): 177-82.
[http://dx.doi.org/10.1111/cup.12863] [PMID: 27862184]
[131]
Watts RA. Drug-induced vasculitisVasculitis in Clinical Practice. Springer 2015; pp. 178-9.
[132]
ten Holder SM, Joy MS, Falk RJ. Cutaneous and systemic manifestations of drug-induced vasculitis. Ann Pharmacother 2002; 36(1): 130-47.
[http://dx.doi.org/10.1345/aph.1A124] [PMID: 11816242]
[133]
Radić M, Martinović Kaliterna D, Radić J. Drug-induced vasculitis: a clinical and pathological review. Neth J Med 2012; 70(1): 12-7.
[PMID: 22271809]
[134]
Grau RG. Drug-Induced Vasculitis: New insights and a changing lineup of suspects. Curr Rheumatol Rep 2015; 17(12): 71.
[http://dx.doi.org/10.1007/s11926-015-0545-9] [PMID: 26503355]
[135]
Wiik A. Drug-induced vasculitis. Curr Opin Rheumatol 2008; 20(1): 35-9.
[http://dx.doi.org/10.1097/BOR.0b013e3282f1331f] [PMID: 18281855]
[136]
Shelly Rivas S, Amit G. Pandy AG, Arturo R. Dominguez AR. Drug-induced vasculitis. In: Hall BR and Hall JC Cutaneous Drug Eruptions: Diagnosis, Histopathology and Therapy. 2nd ed: Springer 2015; 77-85.
[137]
Wiik A. Clinical and laboratory characteristics of drug-induced vasculitic syndromes. Arthritis Res Ther 2005; 7(5): 191-2.
[http://dx.doi.org/10.1186/ar1805] [PMID: 16207347]
[138]
Bonaci-Nikolic B, Nikolic MM, Andrejevic S, Zoric S, Bukilica M. Antineutrophil cytoplasmic antibody (ANCA)-associated autoimmune diseases induced by antithyroid drugs: comparison with idiopathic ANCA vasculitides. Arthritis Res Ther 2005; 7(5): R1072-81.
[http://dx.doi.org/10.1186/ar1789] [PMID: 16207324]
[139]
Baird BJ, De Villez RL. Widespread bullous fixed drug eruption mimicking toxic epidermal necrolysis. Int J Dermatol 1988; 27(3): 170-4.
[http://dx.doi.org/10.1111/j.1365-4362.1988.tb04923.x] [PMID: 3286546]
[140]
Bandino JP, Wohltmann WE, Bray DW, Hoover AZ. Naproxen-induced generalized bullous fixed drug eruption. Dermatol Online J 2009; 15(11): 4.
[PMID: 19951640]
[141]
Ada S, Yilmaz S. Ciprofloxacin-induced generalized bullous fixed drug eruption. Indian J Dermatol Venereol Leprol 2008; 74(5): 511-2.
[http://dx.doi.org/10.4103/0378-6323.44324] [PMID: 19052425]
[142]
Cho YT, Lin JW, Chen YC, et al. Generalized bullous fixed drug eruption is distinct from stevens-johnson syndrome/toxic epidermal necrolysis by immunohistopathological features. J Am Acad Dermatol 2014; 70(3): 539-48.
[http://dx.doi.org/10.1016/j.jaad.2013.11.015] [PMID: 24388722]
[143]
Tavares Almeida F, Caldas R, André Oliveira Á, Pardal J, Pereira T, Brito C. Generalized bullous fixed drug eruption caused by ibuprofen. Contact Dermat 2019; 80(4): 238-9.
[http://dx.doi.org/10.1111/cod.13176] [PMID: 30430598]
[144]
Lipowicz S, Sekula P, Ingen-Housz-Oro S, et al. Prognosis of generalized bullous fixed drug eruption: comparison with stevens-johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 2013; 168(4): 726-32.
[http://dx.doi.org/10.1111/bjd.12133] [PMID: 23413807]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 25
ISSUE: 36
Year: 2019
Page: [3840 - 3854]
Pages: 15
DOI: 10.2174/1381612825666191107162921
Price: $65

Article Metrics

PDF: 46
HTML: 11